| 7th Annual More/Fitness Half Marathon - Video MORE THAN 6,000 WOMEN MADE RACING IN THE RAIN LOOK EASY AT THE SEVENTH-ANNUAL MORE MAGAZINE | FITNESS MAGAZINE WOMEN'S HALF- MARATHON IN CENTRAL PARK feedproxy.google.com |
Genoptix Provides First Look at Second Quarter Results and Updates 2010 Guidance (PR Newswire) Genoptix, Inc. , a specialized laboratory services provider, today provided a first look at performance for the second quarter of 2010 and announced an update to annual guidance expectations for full-year 2010.  us.rd.yahoo.com |
Beyond the Hype: Intuitive Surgical's Hidden Growth Potential Ephemeral Euphoria submits: Back in 2007, when I made my first investment in Intuitive Surgical (ISRG), the maker of the da Vinci surgical robotic system, it was a nondescript, up-and-coming SMidcap followed more by swing traders than sell-side analysts, institutional investors, and the traditional investing masses. click to enlargeComplete Story » seekingalpha.com |
Another Big Bet on Obesity: Takeda Puts Orexigen on Solid Ground The Burrill Report submits: By Michael FitzhughJapan's Takeda (TKPHF.PK) is placing summer’s second major bet on an obesity drug with a $50 million investment in Orexigen's (OREX) Contrave, a combination drug meant to help people tackle the biology and behaviors behind overeating. Payments of more than $1 billion await Orexigen if it hits unspecified regulatory and sales-based milestones in the United States, Canada, and Mexico, the countries covered by its new deal with Takeda. Complete Story » seekingalpha.com |
European Regulators Remove GSK's Avandia From Market: Biotech's Latest Mishaps The Burrill Report submits: The European Medicines Agency is removing GlaxoSmithKline’s (GSK) diabetes drug Avandia from the market because the drug may increase a patient’s risk of heart failure. The U.S. Food and Drug Administration, in a coordinated announcement with the European regulator, agreed that the drug carries risks, but has decided to allow Avandia to remain on the market as a drug of last resort for patients that they have notified of the risks of heart failure associated with the drug. Avandia, once the best selling diabetes drug and the second best-seller in GSK’s product line, has seen sales of the drug drop dramatically since the controversy over its safety erupted. In 2009 sales reached nearly $1.2 billion, down from $3.2 billion in 2006. Sanofi-Aventis (SNY) said that its experimental treatment for limb ischemia failed in a late-stage clinical trail. The primary endpoint was to demonstrate the superiority of drug known as NV1FGF compared to a placebo in the prevention of major amputation or death from any cause over 12 months, whichever came first, in critical limb ischemia patients who were not eligible for revascularization. The company said it is evaluating its options on the development of the drug. Complete Story » seekingalpha.com |